Multiple Myeloma News

Multiple Myeloma News

Infections Observed in Half of MM Patients Treated With Bispecific Antibodies

Publish Date March 17, 2023

Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.

Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure

Publish Date March 16, 2023

Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.

5 Factors That May Affect Multiple Myeloma Outcomes

Publish Date March 9, 2023

What are some of the most important factors affecting outcomes in patients with multiple myeloma?

Second Primary Malignancies After Auto-HSCT Linked to Inferior Outcomes in MM

Publish Date March 7, 2023

Multiple myeloma patients who develop second primary malignancies after auto-HSCT have worse survival outcomes, a study suggests.

Factors Linked to Worse CAR-T Outcomes in High-Risk Multiple Myeloma

Publish Date March 6, 2023

High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests.

Elranatamab Under Review for Relapsed or Refractory Multiple Myeloma

Publish Date February 27, 2023

The FDA has accepted for priority review the biologics license application for elranatamab to be used as a treatment for patients with relapsed or refractory multiple myeloma.

Pano/GBM Plus ASCT Deemed Safe and Effective in High-Risk or Rel/Ref MM

Publish Date February 22, 2023

Pano/GBM is safe and effective as conditioning before ASCT in patients with high-risk or relapsed/refractory multiple myeloma, a study suggests.

Ide-Cel Bests Standard Care in Relapsed/Refractory Multiple Myeloma

Publish Date February 15, 2023

Ide-cel improves outcomes in patients with triple-class-exposed multiple myeloma, when compared with standard care, a phase 3 trial suggests.

Patients With Double-Hit Multiple Myeloma Have Inferior Outcomes After Transplant

Publish Date February 13, 2023

The presence of 2 or more cytogenetic risk markers is associated with inferior outcomes after transplant in patients with multiple myeloma.

Triplet Maintenance Extends PFS After Transplant in Multiple Myeloma

Publish Date January 24, 2023

Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.

Inflammatory-Nutritional Score Helps Predict Survival in Multiple Myeloma

Publish Date January 23, 2023

A nomogram based on the inflammatory-nutritional score may help predict survival in patients with newly diagnosed multiple myeloma.

Daratumumab Extends OS in Relapsed/Refractory Multiple Myeloma

Publish Date January 13, 2023

Adding daratumumab to lenalidomide and dexamethasone extends overall survival in relapsed/refractory multiple myeloma, according to final results from the POLLUX trial.

Posoleucel Deemed Effective Against Viral Infections in Allogeneic HSCT Recipients 

Publish Date January 13, 2023

Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.

ASH 2022: Promising Results in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

Publish Date January 4, 2023

The MonumenTAL-1, MajesTEC-2, OPTIMUM/MUKnine, and GMMG-CONCEPT trials have shown promising results for patients with newly diagnosed or relapsed/refractory multiple myeloma.

Delaying HSCT More Than 4 Weeks After COVID-19 Diagnosis May Decrease Risk of Death

Publish Date January 4, 2023

Undergoing HSCT within 4 weeks of SARS-CoV-2 infection is associated with an increased risk of death at 90 days after HSCT, real-world data suggest.

Dexamethasone-Sparing Regimen Shows Promise in Frail Patients With MM

Publish Date December 27, 2022

A dexamethasone-sparing treatment strategy is safe and effective for frail patients with newly diagnosed multiple myeloma, according to researchers.

Frontline Regimens for MM Are Similar Across the World; Later Lines of Treatment Vary

Publish Date December 22, 2022

Worldwide, bortezomib-based triplets are the most common frontline treatment for multiple myeloma, but regimens used in later lines vary.

Quadruplet Produces Deep Responses in High-Risk, Newly Diagnosed Multiple Myeloma

Publish Date December 14, 2022

Isatuximab plus carfilzomib, lenalidomide, and dexamethasone can produce deep responses in patients with high-risk, newly diagnosed multiple myeloma, a phase 2 trial suggests.

Teclistamab Plus Daratumumab and Lenalidomide Shows Promise in Rel/Ref Multiple Myeloma

Publish Date December 11, 2022

Teclistamab plus daratumumab and lenalidomide produced deep and durable responses in patients with relapsed or refractory multiple myeloma.

Talquetamab Elicits Responses in Relapsed/Refractory Multiple Myeloma

Publish Date December 10, 2022

Talquetamab produced responses in more than 70% of patients with relapsed/refractory multiple myeloma who received the recommended phase 2 doses.